- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03048994
Glutamine Supplementation in Critically Ill Patients With Severe Sepsis (CGH-GLU)
February 7, 2017 updated by: Changi General Hospital
A Randomized Controlled Trial of Glutamine Supplementation in Critically Ill Adults With Severe Sepsis: A Pilot Study
Severe sepsis is a common condition with high mortality and morbidity.
A previous meta-analysis has demonstrated the safety of glutamine supplementation with suggestion of mortality and morbidity benefits in critically ill patients.
But there is lack of evidence to recommend the use of intravenous glutamine supplementation in this population group.
A randomized controlled trial which is adequately powered will resolve this issue and can be included in future international nutrition guidelines for the critically ill.
This pilot study is done prior to a proposed local multi-center study to investigate the effects of glutamine supplementation.
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Detailed Description
Objective
- To determine the effect of intravenous glutamine supplementation compared with placebo in critically ill patients with severe sepsis
- Primary outcome : 28 day mortality , Development of infectious complications
Secondary outcomes
- Duration of mechanical ventilation
- Length of stay in ICU
- Length of stay in hospital
- 3 month survival status and resumption of baseline activities
- 6 month survival status and resumption of baseline activities
Study Design
- Single center, prospective, double blind, randomised controlled trial critically ill patients with severe sepsis
Randomisation
- A centralised randomisation system at SCRI (Singapore Clinical Research institute)
- Allocation will be random and concealed, and will be blinded to everyone except the pharmacist at each site, who will be responsible for preparing and delivering them to the ICU in a blinded fashion.
Intervention
- Patients randomised to receive glutamine supplementation will receive IV glutamine (0.5g/kg body weight/day) continuously over 24 hours.
- IV glutamine will be administered for 5 days or less if death ensues prior to 5 days or transferred to another hospital prior to 5 days. IV glutamine will be continued even if the patient is transferred outside the ICU but within the hospital.
- An intravenous saline solution that is identical in volume, color and consistency will be administered to the placebo group with the same dosing regimen and duration.
Cointerventions
- Nutritional support will be continued as per managing ICU team discretion.
- Management of severe sepsis will be continued as per managing ICU team discretion.
- Weaning patients from mechanical ventilation will be done as per managing ICU team discretion.
- To minimise differences between centers, active dissemination of practice guidelines for nutritional support, sepsis management and weaning will be carried out.
Execution of study protocol
- The managing ICU team will be responsible in identifying patients that meet the inclusion and exclusion criteria and will inform the site research coordination
The site research coordinator will be responsible for the following
- Obtaining consent from relatives of the patients
- Informing the site pharmacist about the recruited patients
- Follow study patients prospectively while in the ICU, hospital and post discharge at 3 and 6 months.
- Completing the case report from for each study participant
- Submitting case report forms, completed and interim reports, to coordinating statistical team
Pharmacist
- Site pharmacist to liase with SCRI on randomised patients status (treatment vs. placebo)
- Prepare the intervention treatment and placebo
- Deliver the treatment and placebo to the respective patients.
Nurses
- Responsible for administering the delivered medications
- Ensure and documenting compliance with administration, reasons for interruptions and documenting adverse reactions.
- Liasing with the site research coordinator daily regarding the above.
- Liasing with the site research coordinator on transfer, discharge or death of study participants
Study Type
Interventional
Enrollment (Actual)
39
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
-
Singapore, Singapore
- Changi General Hospital
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
21 years to 99 years (ADULT, OLDER_ADULT)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria
- All adult patients (>18 years old) admitted to ICU plus
Severe sepsis defined as 2 or more or the following
- Temperature >38oC or < 36oC
- Heart rate > 90 beats per min
- Respiratory rate >20 breaths per min or PaCO2 <32 mmHg
White cell count > 12,000/microL or < 4,000/microL
- PLUS presence or presumed presence of infection
- PLUS evidence of organ dysfunction as defined by either of the following
- Hemodynamic: Hypotension = systolic blood pressure (SBP) 40 mm Hg or mean arterial pressure (MAP) < 65 mm Hg; or on vasopressors
- Hyperlactatemia: Serum lactate >/= 2 mmol/L (18 mg/dL)
- Renal: Acute increase in serum creatinine to > 176.8 mmol/L (2.0 mg/dL) or urine output < 0.5 mL/kg/hour for > 2 hours
- Lung: Acute lung injury with PaO2/FiO2 </=300mmHg
- Liver: Acute increase in bilirubin to >/= 34.2 umol/L (2 mg/dL)
- Thrombocytopenia: Acute decrease in platelet count to < 100,000 cells/mm3
- Coagulopathy: International normalized ratio (INR) > 1.5 or a partial thromboplastin time (aPTT) > 60 secs which is not due to anticoagulant therapy
- Exclusion criteria
- >48hr from admission to ICU
- Patients who are not expected to survive >48hrs by the managing team
- Refusal to consent to study
- Allergic to glutamine or its constituents
- Absolute contraindication to enteral nutrition or the need to initiate parenteral nutrition
- Patients with a primary admission diagnosis of burns (>30% body surface area)
- Patients whose weight <40kg or >200kg
- Previous randomization to this study
- Enrolled in a related ICU interventional nutrition study
- Pregnant patients or lactating mothers with the intent to breastfeed
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: TREATMENT
- Allocation: RANDOMIZED
- Interventional Model: PARALLEL
- Masking: QUADRUPLE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
PLACEBO_COMPARATOR: Placebo
|
|
ACTIVE_COMPARATOR: Glutamine
|
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Mortality
Time Frame: 28 day
|
28 day
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Occurrence of new infections
Time Frame: Initial hospital admission, assessed up to 130 days.
|
Initial hospital admission, assessed up to 130 days.
|
ICU length of stay (LOS)
Time Frame: From date of ICU admission to date of transferred to General Ward or date of death from any cause, whichever came first, assessed up to 21 days.
|
From date of ICU admission to date of transferred to General Ward or date of death from any cause, whichever came first, assessed up to 21 days.
|
Hospital LOS
Time Frame: From date of recruitment to date of discharged from hospital or date of transferred to other hospitals or date of death from any cause, whichever came first, assessed up to 130 days.
|
From date of recruitment to date of discharged from hospital or date of transferred to other hospitals or date of death from any cause, whichever came first, assessed up to 130 days.
|
Duration of mechanical ventilation
Time Frame: During period of ICU stay, assessed up to 14 days.
|
During period of ICU stay, assessed up to 14 days.
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Collaborators
Investigators
- Principal Investigator: Vijo Poulose, Changi General Hospital
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
General Publications
- Novak F, Heyland DK, Avenell A, Drover JW, Su X. Glutamine supplementation in serious illness: a systematic review of the evidence. Crit Care Med. 2002 Sep;30(9):2022-9. doi: 10.1097/00003246-200209000-00011.
- Roth E, Funovics J, Muhlbacher F, Schemper M, Mauritz W, Sporn P, Fritsch A. Metabolic disorders in severe abdominal sepsis: glutamine deficiency in skeletal muscle. Clin Nutr. 1982 Mar;1(1):25-41. doi: 10.1016/0261-5614(82)90004-8.
- Heyland DK, Dhaliwal R, Suchner U, Berger MM. Antioxidant nutrients: a systematic review of trace elements and vitamins in the critically ill patient. Intensive Care Med. 2005 Mar;31(3):327-37. doi: 10.1007/s00134-004-2522-z. Epub 2004 Dec 17.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
January 1, 2011
Primary Completion (ACTUAL)
June 1, 2013
Study Completion (ACTUAL)
June 1, 2013
Study Registration Dates
First Submitted
September 24, 2012
First Submitted That Met QC Criteria
February 7, 2017
First Posted (ESTIMATE)
February 9, 2017
Study Record Updates
Last Update Posted (ESTIMATE)
February 9, 2017
Last Update Submitted That Met QC Criteria
February 7, 2017
Last Verified
February 1, 2017
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- CTC1000338
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
NO
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Severe Sepsis
-
Indonesia UniversityCompletedSevere Sepsis With Septic Shock | Severe Sepsis Without Septic ShockIndonesia
-
Beckman Coulter, Inc.Biomedical Advanced Research and Development AuthorityRecruitingSevere Sepsis | Severe Sepsis Without Septic ShockUnited States
-
Rennes University HospitalUnknownSevere Sepsis or Septic Shock
-
Beckman Coulter, Inc.CompletedSepsis | Severe Sepsis | Severe InfectionFrance, Spain
-
Yonsei UniversityCompletedSevere Sepsis or Septic ShockKorea, Republic of
-
University of RostockCompletedSevere Sepsis and Septic ShockGermany
-
Centre Hospitalier Universitaire de NiceUnknownComparison of Sensitivity Between Presepsine and Lactate for the Diagnosis of Severe Sepsis. (PREDI)Severe Sepsis and Septic ShockFrance
-
University Hospital, Strasbourg, FranceUnknownSevere Sepsis and Septic ShockFrance
-
Peking Union Medical College HospitalUnknownLactate | Severe Sepsis With Septic Shock
-
University of UtahNational Institutes of Health (NIH)CompletedSevere Sepsis With Septic Shock
Clinical Trials on Placebo
-
SamA Pharmaceutical Co., LtdUnknownAcute Bronchitis | Acute Upper Respiratory Tract InfectionKorea, Republic of
-
National Institute on Drug Abuse (NIDA)CompletedCannabis UseUnited States
-
AstraZenecaParexel; Spandauer Damm 130; 14050; Berlin, GermanyCompletedMale Subjects With Type II Diabetes (T2DM)Germany
-
Heptares Therapeutics LimitedCompletedPharmacokinetics | Safety IssuesUnited Kingdom
-
GlaxoSmithKlineCompletedPulmonary Disease, Chronic ObstructiveUnited Kingdom, Netherlands
-
ItalfarmacoCompletedBecker Muscular DystrophyNetherlands, Italy
-
Shijiazhuang Yiling Pharmaceutical Co. LtdXuanwu Hospital, BeijingCompleted
-
GlaxoSmithKlineCompletedInfections, BacterialUnited States
-
West Penn Allegheny Health SystemCompletedAsthma | Allergic RhinitisUnited States